{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T21:40:18Z","timestamp":1731447618236,"version":"3.28.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"DOI":"10.7759\/cureus.73550","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T21:05:02Z","timestamp":1731445502000},"source":"Crossref","is-referenced-by-count":0,"title":["Serological Profiles of Hepatitis B Virus in Patients With Crohn\u2019s Disease Undergoing Anti-Tumor Necrosis Factor Alpha (TNF\u03b1) Therapy at Ibn Sina University Hospital, Rabat"],"prefix":"10.7759","author":[{"given":"Imane","family":"Louhab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajar","family":"Daoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Elcadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghizlane","family":"El Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Zouaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalila","family":"Zirar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Seffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna","family":"Salihoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakima","family":"Kabbaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.mchd-0022-2015","article-title":"Anti-TNF therapy","volume":"4","author":"Udalova I","year":"2016","unstructured":"Udalova I, Monaco C, Nanchahal J, Feldmann M. Anti-TNF therapy. Microbiol Spectr. 2016, 4:10.1128\/microbiolspec.mchd-0022-2015","journal-title":"Microbiol Spectr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082244","article-title":"Anti-TNF therapy in Crohn's disease","volume":"19","author":"Adegbola SO","year":"2018","unstructured":"Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn's disease. Int J Mol Sci. 2018, 19:2244. 10.3390\/ijms19082244","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh S","year":"2021","unstructured":"Singh S, Murad MH, Fumery M, et al.. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021, 6:1002-14. 10.1016\/S2468-1253(21)00312-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin AD","year":"2016","unstructured":"Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016, 10:989-97. 10.1093\/ecco-jcc\/jjw053","journal-title":"J Crohns Colitis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco C","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015, 27:55-62. 10.1093\/intimm\/dxu102","journal-title":"Int Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.03.013","article-title":"Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation","volume":"191","author":"Clarke WT","year":"2018","unstructured":"Clarke WT, Amin SS, Papamichael K, Feuerstein JD, Cheifetz AS. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation. Clin Immunol. 2018, 191:59-62. 10.1016\/j.clim.2018.03.013","journal-title":"Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14034","article-title":"Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-\u03b1 therapy","volume":"24","author":"Fidan S","year":"2021","unstructured":"Fidan S, Capk\u0131n E, Ar\u0131ca DA, Durak S, Okatan IE. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-\u03b1 therapy. Int J Rheum Dis. 2021, 24:254-9. 10.1111\/1756-185X.14034","journal-title":"Int J Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-50","article-title":"Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco","volume":"13","author":"Baha W","year":"2013","unstructured":"Baha W, Foullous A, Dersi N, et al.. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health. 2013, 13:50. 10.1186\/1471-2458-13-50","journal-title":"BMC Public Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000518618","article-title":"Prevalence of hepatitis B virus infection markers among patients of the Ibn Sina University Hospital Center (Rabat, Morocco)","volume":"65","author":"Feindiri M","year":"2022","unstructured":"Feindiri M, Kabbaj H, El Mzibri M, Belkadi B, Bouihat N, Filali-Maltouf A, Seffar M. Prevalence of hepatitis B virus infection markers among patients of the Ibn Sina University Hospital Center (Rabat, Morocco). Intervirology. 2022, 65:80-6. 10.1159\/000518618","journal-title":"Intervirology"},{"key":"ref10","unstructured":"Guidelines on hepatitis B and C testing. (2017). https.\/\/www.who.int\/publications\/i\/item\/9789241549981."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2011.07.013","article-title":"Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm [Article in French]","volume":"33","author":"Terrier B","year":"2012","unstructured":"Terrier B, Pol S, Thibault V, Gottenberg JE, Cacoub P. Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm [Article in French]. Rev Med Interne. 2012, 33:4-12. 10.1016\/j.revmed.2011.07.013","journal-title":"Rev Med Interne"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","unstructured":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017, 67.370-98. 10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"ref13","unstructured":"Biological screening strategies for viral hepatitis B and C [Report in French]. (2011). https.\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2012-01\/strategies_de_depistage_biologique_des_hepatites_virales...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0399-8320(08)73266-4","article-title":"Virologic techniques for the diagnosis and monitoring of hepatitis B [Article in French]","volume":"32","author":"Pawlotsky JM","year":"2008","unstructured":"Pawlotsky JM. Virologic techniques for the diagnosis and monitoring of hepatitis B [Article in French]. Gastroenterol Clin Biol. 2008, 32:56-63. 10.1016\/S0399-8320(08)73266-4","journal-title":"Gastroenterol Clin Biol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2019.03.333","article-title":"Hepatitis B virus infection: natural history, clinical manifestations and therapeutic approach [Article in French]","volume":"40","author":"Paccoud O","year":"2019","unstructured":"Paccoud O, Surgers L, Lacombe K. Hepatitis B virus infection: natural history, clinical manifestations and therapeutic approach [Article in French]. Rev Med Interne. 2019, 40:590-8. 10.1016\/j.revmed.2019.03.333","journal-title":"Rev Med Interne"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.07.006","article-title":"Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study","volume":"46","author":"van der Have M","year":"2014","unstructured":"van der Have M, Belderbos TD, Fidder HH, et al.. Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Dig Liver Dis. 2014, 46:881-6. 10.1016\/j.dld.2014.07.006","journal-title":"Dig Liver Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27806","article-title":"Tumor necrosis factor inhibitor therapy for hepatitis B virus-infected individuals: how loud is the alarm bell?","volume":"62","author":"Perrillo RP","year":"2015","unstructured":"Perrillo RP. Tumor necrosis factor inhibitor therapy for hepatitis B virus-infected individuals: how loud is the alarm bell?. Hepatology. 2015, 62:16-8. 10.1002\/hep.27806","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras C","year":"2010","unstructured":"Loras C, Gisbert JP, M\u00ednguez M, et al.. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010, 59:1340-6. 10.1136\/gut.2010.208413","journal-title":"Gut"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve M","year":"2004","unstructured":"Esteve M, Saro C, Gonz\u00e1lez-Huix F, Suarez F, Forn\u00e9 M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004, 53:1363-5. 10.1136\/gut.2004.040675","journal-title":"Gut"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021527","article-title":"Management of chronic hepatitis B in patients from special populations","volume":"5","author":"Lai CL","year":"2015","unstructured":"Lai CL, Yuen MF. Management of chronic hepatitis B in patients from special populations. Cold Spring Harb Perspect Med. 2015, 5:10.1101\/cshperspect.a021527","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200111000-00002","article-title":"Hepatitis B and C virus infection in Crohn's disease","volume":"7","author":"Biancone L","year":"2001","unstructured":"Biancone L, Pavia M, Del Vecchio Blanco G, et al.. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis. 2001, 7:287-94. 10.1097\/00054725-200111000-00002","journal-title":"Inflamm Bowel Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.4","article-title":"Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study","volume":"104","author":"Loras C","year":"2009","unstructured":"Loras C, Saro C, Gonzalez-Huix F, et al.. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol. 2009, 104:57-63. 10.1038\/ajg.2008.4","journal-title":"Am J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy KR","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015, 148:215-9; quiz e16-7. 10.1053\/j.gastro.2014.10.039","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier JF","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C, et al.. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014, 8:443-68. 10.1016\/j.crohns.2013.12.013","journal-title":"J Crohns Colitis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00201-1","article-title":"Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis","volume":"7","author":"Im YR","year":"2022","unstructured":"Im YR, Jagdish R, Leith D, et al.. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022, 7:932-42. 10.1016\/S2468-1253(22)00201-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the Taormina expert meeting on occult hepatitis B virus infection","volume":"49","author":"Raimondo G","year":"2008","unstructured":"Raimondo G, Allain JP, Brunetto MR, et al.. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008, 49:652-7. 10.1016\/j.jhep.2008.07.014","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20035","article-title":"Occult hepatitis B and infliximab-induced HBV reactivation","volume":"13","author":"Madonia S","year":"2007","unstructured":"Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007, 13:508-9. 10.1002\/ibd.20035","journal-title":"Inflamm Bowel Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.5009\/gnl210081","article-title":"Clinical course of hepatitis B viral infection in patients undergoing anti-tumor necrosis factor \u03b1 therapy for inflammatory bowel disease","volume":"16","author":"Lee JM","year":"2022","unstructured":"Lee JM, Wei SC, Lee KM, et al.. Clinical course of hepatitis B viral infection in patients undergoing anti-tumor necrosis factor \u03b1 therapy for inflammatory bowel disease. Gut Liver. 2022, 16:396-403. 10.5009\/gnl210081","journal-title":"Gut Liver"},{"key":"ref29","article-title":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy","volume":"31","author":"Lee YH","year":"2013","unstructured":"Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013, 31:118-21.","journal-title":"Clin Exp Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-020-01069-0","article-title":"A comprehensive review of vaccination in patients with inflammatory bowel diseases: an Indian perspective","volume":"39","author":"Shah BB","year":"2020","unstructured":"Shah BB, Goenka MK. A comprehensive review of vaccination in patients with inflammatory bowel diseases: an Indian perspective. Indian J Gastroenterol. 2020, 39:321-30. 10.1007\/s12664-020-01069-0","journal-title":"Indian J Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04112.x","article-title":"Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease","volume":"31","author":"Shale MJ","year":"2010","unstructured":"Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010, 31:20-34. 10.1111\/j.1365-2036.2009.04112.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.080","article-title":"Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"35","author":"Jiang HY","year":"2017","unstructured":"Jiang HY, Wang SY, Deng M, Li YC, Ling ZX, Shao L, Ruan B. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine. 2017, 35:2633-41. 10.1016\/j.vaccine.2017.03.080","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05110.x","article-title":"Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease","volume":"35","author":"Gisbert JP","year":"2012","unstructured":"Gisbert JP, Mench\u00e9n L, Garc\u00eda-S\u00e1nchez V, Mar\u00edn I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012, 35:1379-85. 10.1111\/j.1365-2036.2012.05110.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00646.x","article-title":"Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses","volume":"101","author":"Melmed GY","year":"2006","unstructured":"Melmed GY, Ippoliti AF, Papadakis KA, et al.. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006, 101:1834-40. 10.1111\/j.1572-0241.2006.00646.x","journal-title":"Am J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13001","article-title":"Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients","volume":"30","author":"Andrade P","year":"2015","unstructured":"Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015, 30:1591-5. 10.1111\/jgh.13001","journal-title":"J Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2016.0024","article-title":"Prevention of hepatitis B reactivation in the setting of immunosuppression","volume":"22","author":"Pattullo V","year":"2016","unstructured":"Pattullo V. Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016, 22:219-37. 10.3350\/cmh.2016.0024","journal-title":"Clin Mol Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo RP","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015, 148:221-44.e3. 10.1053\/j.gastro.2014.10.038","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora J","year":"2014","unstructured":"Lucifora J, Xia Y, Reisinger F, et al.. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014, 343:1221-8. 10.1126\/science.1243462","journal-title":"Science"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.01.015","article-title":"Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation","volume":"81","author":"Lunel-Fabiani F","year":"2014","unstructured":"Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine. 2014, 81:478-84. 10.1016\/j.jbspin.2014.01.015","journal-title":"Joint Bone Spine"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1523-2","article-title":"Use of tumor necrosis factor \u03b1 inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action","volume":"29","author":"Carroll MB","year":"2010","unstructured":"Carroll MB, Forgione MA. Use of tumor necrosis factor \u03b1 inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010, 29:1021-9. 10.1007\/s10067-010-1523-2","journal-title":"Clin Rheumatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-008-2165-x","article-title":"Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab","volume":"43","author":"Ojiro K","year":"2008","unstructured":"Ojiro K, Naganuma M, Ebinuma H, et al.. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol. 2008, 43:397-401. 10.1007\/s00535-008-2165-x","journal-title":"J Gastroenterol"},{"key":"ref42","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?","volume":"12","author":"Millonig G","year":"2006","unstructured":"Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol. 2006, 12:974-6.","journal-title":"World J Gastroenterol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alvarez R","year":"2011","unstructured":"P\u00e9rez-Alvarez R, D\u00edaz-Lagares C, Garc\u00eda-Hern\u00e1ndez F, et al.. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011, 90:359-71. 10.1097\/MD.0b013e3182380a76","journal-title":"Medicine (Baltimore)"},{"key":"ref44","article-title":"Fulminant acute hepatitis B after infliximab treatment in Crohn's disease [Article in French]","volume":"92","author":"Olfa H","year":"2014","unstructured":"Olfa H, Aroua G, Wissem M, et al.. Fulminant acute hepatitis B after infliximab treatment in Crohn's disease [Article in French]. Tunis Med. 2014, 92:349-50.","journal-title":"Tunis Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8907","article-title":"Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation","volume":"7","author":"Zhang MY","year":"2016","unstructured":"Zhang MY, Zhu GQ, Shi KQ, et al.. Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016, 7:30642-58. 10.18632\/oncotarget.8907","journal-title":"Oncotarget"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok AS","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009, 50:661-2. 10.1002\/hep.23190","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/307999-serological-profiles-of-hepatitis-b-virus-in-patients-with-crohns-disease-undergoing-anti-tumor-necrosis-factor-alpha-tnf-therapy-at-ibn-sina-university-hospital-rabat","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T21:05:04Z","timestamp":1731445504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/307999-serological-profiles-of-hepatitis-b-virus-in-patients-with-crohns-disease-undergoing-anti-tumor-necrosis-factor-alpha-tnf-therapy-at-ibn-sina-university-hospital-rabat"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.73550","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}